drugset / Trial / NCT03221582
Impact of Hepatitis C Therapy and Bone Health
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An evaluation of the impact of Elbasvir and Grazoprevir (EBR/GZR) HCV therapy on the heart risk and bone health of HCV mono-infected and HIV/HCV co-infected patients.
Timeline
- Start
- 2017-08-28
- Primary completion
- 2018-11-26
- Completion
- 2018-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elbasvir | Small molecule | 50 mg | Oral |
| Subject | GRAZOPREVIR ANHYDROUS | Small molecule | 100 mg | Oral |